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CIP acquisition of third-party technology related to late blight resistance in potato for introduction 
into improved varieties and dissemination to farmers in Uganda and regionally. 
 
Background: The agreement provides CIP access to a late-blight-resistance gene (RB gene) for 
introduction into improved varieties and release as transgenic varieties in developing countries under 
terms and conditions designed to facilitate access by developing country farmers on a fair and 
reasonable cost basis subject to stewardship requirements. This technology is proprietary and 
comparable traits with similar agronomic performance are not available to CIP. 
 
Potential benefit to smallholders: In Uganda, where about 300,000 smallholder households grow 
potatoes for subsistence and income, the disease can destroy as much as 60% of a farmer’s potato crop, 
which translates into annual losses of approximately $129 million. Farmers commonly use fungicides to 
control late blight, but those agrochemicals are costly, the pathogen gradually adepts to them, and they 
pose potential risks to human health and the environment. Hence, the new transgenic varieties 
anticipated to be widely adopted by farmers provides the benefits of growing a variety of potatoes that 
are familiar to farmers and consumers without the need to use fungicide. In addition to lowering 
farmers’ production costs and improving their harvests, the late-blight-resistant potato will reduce the 
health impact that fungicides pose in potato-farming regions.  
 
Dissemination strategy, stewardship plan, and regulatory compliance: CIP disseminates its technologies 
via partners who oversee their commercialization to the intended users. In Uganda, the new transgenic 
varieties containing the RB gene and other resistance genes will be multiplied by the National 
Agriculture Research Organization and/or private seed providers following good stewardship practices 
and sold to farmers in a similar manner as conventional varieties; however, this release may be subject 
to restrictions stipulated by the National Biosafety Bill which are still unknown until approved by the 
parliament and the president. To comply with the regulatory and biosafety requirement and 
stewardship, this technology will likely not reach farmers for several years. CIP has included a public 
communication on its website containing key information concerning the Restricted Use Agreement. 
The project is at proof of concept stage and CIP anticipates making further public communications as the 
project advances through key milestones. 
